The key analytical signal is a sequence that crosses the joining point between the two gene-derived segments. Because normal gene products do not contain that same junction, junction-spanning reads or amplified products can distinguish a candidate fusion from expected transcripts. This makes the junction the central evidence used during targeted amplification, sequencing, or alignment.
Converting RNA into complementary DNA creates a form that can be examined by the downstream detection approaches described for this analysis. The resulting cDNA can then serve as the input for targeted amplification, sequencing, or alignment, allowing investigators to search specifically for junction-spanning sequences. This step connects the original RNA signal to measurable molecular evidence.
Targeted amplification, sequencing, and alignment provide different ways to recognize the same type of evidence. Amplification focuses analysis on selected transcript regions, whereas sequencing can provide sequence information for identifying joined segments; alignment evaluates sequence relationships that reveal a junction. Choosing among them depends on the detection question and the kind of evidence needed.
A basic workflow begins with RNA, converts it to complementary DNA, and applies a detection strategy directed toward possible fusion junctions. Investigators may use targeted amplification, sequencing, or alignment to examine the resulting material. The analysis then focuses on whether sequences spanning two distinct gene segments are present, producing evidence for a rearrangement or abnormal transcription.
In immunology and infection research, the approach can be applied to immune-cell samples to investigate oncogenic rearrangements, or to microbial and viral contexts to characterize integration events involving host genetic material. These uses extend beyond merely finding a transcript: they help connect molecular joining events with immune-cell signaling, infection-related processes, or host-pathogen interactions.
Detected junctions can support disease classification and biomarker development, while also informing studies of how genetic alterations affect cellular signaling. In infection-related and immune-mediated disorders, the findings can help clarify whether an observed molecular change reflects a rearrangement, abnormal transcription, or a pathogen-host interaction. Interpretation therefore links sequence evidence with disease and mechanistic questions.